New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer

By Schønnemann Katrine R.   Yilmaz Mette   Andersen Maria   Pfeiffer Per  

Acta Oncologica, Vol. 50, Iss. 1, 2011-01 ,pp. : 151-152

Informa Healthcare

Access to resources Recommend Favorite

A Phase I Study Of Docetaxel, Oxaliplatin, & Capecitabine (DOC) As First-Line Therapy of Patients With Locally Advanced or Metastatic Adenocarcinoma of Stomach and GE Junction

By Malik Imtiaz   Bernal Pedro   Byrd Janet  

Cancer Investigation, Vol. 28, Iss. 8, 2010-09 ,pp. : 833-838

Informa Healthcare

Access to resources Recommend Favorite

Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer

By Dupont Jeanette   Jensen Helle A.   Jensen Benny V.   Pfeiffer Per  

Acta Oncologica, Vol. 46, Iss. 3, 2007-01 ,pp. : 330-335

Informa Healthcare

Access to resources Recommend Favorite

Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study

By Santini Daniele   Vincenzi Bruno   Schiavon Gaia   Di Seri Marisa   Virzí Vladimir   Spalletta Bruno   Caricato Marco   Coppola Roberto   Tonini Giuseppe  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 613-620

Springer Publishing Company

Access to resources Recommend Favorite

A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer

By Chao Yee   Hsieh Jan-Sing   Yeh Hsien-Tang   Su Yu-Chieh   Wu Cheng-Chung   Chen Jen-Shi   Tai Cheng-Jeng   Bai Li-Yuan   Yeh Kun-Huei   Su Wu-Chou   Li Chung-Pin  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 799-806

Springer Publishing Company

Access to resources Recommend Favorite